Cargando…
Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting
Although rituximab is generally well‐tolerated, infusion‐related reactions (IRRs) are common with the initial dose when administered intravenously according to standard recommendations. To prevent IRRs, premedication and low‐speed infusion rates have been recommended. Consequently, intravenous (i.v....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926065/ https://www.ncbi.nlm.nih.gov/pubmed/36385738 http://dx.doi.org/10.1111/cts.13450 |
_version_ | 1784888195137142784 |
---|---|
author | Muntañola, Ana Arguiñano‐Pérez, José María Dávila, Julio de Villambrosia, Sonia González Carpio, Cecilia Jiménez‐Ubieto, Ana Salar, Antonio |
author_facet | Muntañola, Ana Arguiñano‐Pérez, José María Dávila, Julio de Villambrosia, Sonia González Carpio, Cecilia Jiménez‐Ubieto, Ana Salar, Antonio |
author_sort | Muntañola, Ana |
collection | PubMed |
description | Although rituximab is generally well‐tolerated, infusion‐related reactions (IRRs) are common with the initial dose when administered intravenously according to standard recommendations. To prevent IRRs, premedication and low‐speed infusion rates have been recommended. Consequently, intravenous (i.v.) infusion of rituximab can become a labor‐intensive process. Rapid i.v. rituximab infusion over 90 min has demonstrated a favorable safety profile for the second and subsequent infusions during the course of therapy. The aim of this study was to investigate the safety and tolerability of 90‐min rapid infusion of Sandoz rituximab biosimilar (SDZ‐RTX) for patients with CD20+ lymphoma or chronic lymphocytic leukemia (CLL). We retrospectively reviewed all patients with CD20+ lymphoma or CLL who received SDZ‐RTX infusions in 90 min from July 2019 to July 2021 at seven Spanish hospitals. The primary end point was the incidence of IRRs. We identified 124 patients and 576 rapid administrations of SDZ‐RTX, with an average of five rapid infusions per patient. Most rapid infusions of SDZ‐RTX were in combination with CHOP/CHOP‐like therapy (48.4%), followed by SDZ‐RTX alone (15.1%), in combination with bendamustine (14.5%), or with other regimens (22%). The 90‐min SDZ‐RTX infusion schedule was well‐tolerated with no grade 3/4 IRRs. The incidence of any grade IRR during the first rapid infusion was 1% (5 grade 1 IRRs and 1 grade 2 IRR). In conclusion, rapid 90‐min i.v. administration of SDZ‐RTX for the second and subsequent infusions during the course of therapy is well‐tolerated in patients with CD20+ lymphoma or CLL. |
format | Online Article Text |
id | pubmed-9926065 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99260652023-02-16 Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting Muntañola, Ana Arguiñano‐Pérez, José María Dávila, Julio de Villambrosia, Sonia González Carpio, Cecilia Jiménez‐Ubieto, Ana Salar, Antonio Clin Transl Sci Research Although rituximab is generally well‐tolerated, infusion‐related reactions (IRRs) are common with the initial dose when administered intravenously according to standard recommendations. To prevent IRRs, premedication and low‐speed infusion rates have been recommended. Consequently, intravenous (i.v.) infusion of rituximab can become a labor‐intensive process. Rapid i.v. rituximab infusion over 90 min has demonstrated a favorable safety profile for the second and subsequent infusions during the course of therapy. The aim of this study was to investigate the safety and tolerability of 90‐min rapid infusion of Sandoz rituximab biosimilar (SDZ‐RTX) for patients with CD20+ lymphoma or chronic lymphocytic leukemia (CLL). We retrospectively reviewed all patients with CD20+ lymphoma or CLL who received SDZ‐RTX infusions in 90 min from July 2019 to July 2021 at seven Spanish hospitals. The primary end point was the incidence of IRRs. We identified 124 patients and 576 rapid administrations of SDZ‐RTX, with an average of five rapid infusions per patient. Most rapid infusions of SDZ‐RTX were in combination with CHOP/CHOP‐like therapy (48.4%), followed by SDZ‐RTX alone (15.1%), in combination with bendamustine (14.5%), or with other regimens (22%). The 90‐min SDZ‐RTX infusion schedule was well‐tolerated with no grade 3/4 IRRs. The incidence of any grade IRR during the first rapid infusion was 1% (5 grade 1 IRRs and 1 grade 2 IRR). In conclusion, rapid 90‐min i.v. administration of SDZ‐RTX for the second and subsequent infusions during the course of therapy is well‐tolerated in patients with CD20+ lymphoma or CLL. John Wiley and Sons Inc. 2022-11-24 /pmc/articles/PMC9926065/ /pubmed/36385738 http://dx.doi.org/10.1111/cts.13450 Text en © 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Muntañola, Ana Arguiñano‐Pérez, José María Dávila, Julio de Villambrosia, Sonia González Carpio, Cecilia Jiménez‐Ubieto, Ana Salar, Antonio Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting |
title | Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting |
title_full | Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting |
title_fullStr | Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting |
title_full_unstemmed | Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting |
title_short | Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting |
title_sort | safety and tolerability of a 90‐minute rapid infusion of sandoz biosimilar rituximab in b‐cell lymphoproliferative disorders in a real‐world setting |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926065/ https://www.ncbi.nlm.nih.gov/pubmed/36385738 http://dx.doi.org/10.1111/cts.13450 |
work_keys_str_mv | AT muntanolaana safetyandtolerabilityofa90minuterapidinfusionofsandozbiosimilarrituximabinbcelllymphoproliferativedisordersinarealworldsetting AT arguinanoperezjosemaria safetyandtolerabilityofa90minuterapidinfusionofsandozbiosimilarrituximabinbcelllymphoproliferativedisordersinarealworldsetting AT davilajulio safetyandtolerabilityofa90minuterapidinfusionofsandozbiosimilarrituximabinbcelllymphoproliferativedisordersinarealworldsetting AT devillambrosiasoniagonzalez safetyandtolerabilityofa90minuterapidinfusionofsandozbiosimilarrituximabinbcelllymphoproliferativedisordersinarealworldsetting AT carpiocecilia safetyandtolerabilityofa90minuterapidinfusionofsandozbiosimilarrituximabinbcelllymphoproliferativedisordersinarealworldsetting AT jimenezubietoana safetyandtolerabilityofa90minuterapidinfusionofsandozbiosimilarrituximabinbcelllymphoproliferativedisordersinarealworldsetting AT salarantonio safetyandtolerabilityofa90minuterapidinfusionofsandozbiosimilarrituximabinbcelllymphoproliferativedisordersinarealworldsetting AT safetyandtolerabilityofa90minuterapidinfusionofsandozbiosimilarrituximabinbcelllymphoproliferativedisordersinarealworldsetting |